Avid Bioservices, Inc.
2642 Michelle Drive, Suite 200
Tustin
California
92780
United States
Tel: 714-508-6100
Fax: 714-439-1300
Website: http://www.avidbio.com/
About Avid Bioservices, Inc.
Avid Bioservices Inc., located in Tustin CA, is a dedicated contract development and manufacturing organization (“CDMO”) focused on development and CGMP manufacturing of biopharmaceuticals products derived from mammalian cell culture. Avid provides a comprehensive range of process development, high quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 28 years of experience producing monoclonal antibodies, enzymes, and recombinant proteins in batch, fed-batch, and perfusion modes, Avid's services include CGMP clinical and commercial product manufacturing, purification, release and stability testing as well as regulatory strategy, submission and support. Avid also provides a variety of process development activities, including cell culture and feed optimization, analytical methods development, and product characterization.
Stock Symbol: CDMO
Take a virtual 3D tour of our Myford North facility featuring our CGMP single-use drug substance manufacturing suite and quality control labs.
140 articles about Avid Bioservices, Inc.
-
Avid Bioservices Receives Five 2020 CMO Leadership Awards
3/26/2020
Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry Named 2020 CMO Leadership Award Champion in Categories of Expertise and Service TUSTIN, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturin
-
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2020 and Recent Developments
3/10/2020
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the third quarter and first nine months of fiscal 2020 ended January 31, 2020.
-
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - March 04, 2020
3/4/2020
Avid Bioservices, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.
-
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2020 After Market Close on March 10, 2020
3/3/2020
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2020 on March 10, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
-
Avid Bioservices Appoints Timothy Compton as Chief Commercial OfficerCompany Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience
1/8/2020
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the appointment of Timothy Compton as chief commercial officer.
-
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments
12/9/2019
Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18%
-
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock - Dec. 04, 2019
12/4/2019
Avid Bioservices, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.
-
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2020 After Market Close on December 9, 2019
12/2/2019
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2020 on December 9, 2019
-
Avid Bioservices Announces Completion Of Expansion Of Process Development Capabilities And Laboratory Infrastructure
10/8/2019
Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories
-
Avid Bioservices Enters into Contract Manufacturing Agreements with New and Existing Customers
7/8/2019
Company Signs Top Ten Global Pharmaceutical Company as New Client and Expands Relationship with Existing Biotechnology Company Customer
-
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
-
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
6/6/2018
Avid Bioservices, Inc. announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
-
Avid Bioservices (NASD: CDMO) Selected to Provide Process Development and Clinical Manufacture for Novel Alzheimer's Drug
3/1/2018
Avid Bioservices was selected by Acumen Pharmaceuticals to lead process development and clinical manufacturing of novel alzheimer's disease candidate.
-
Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
2/21/2018
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to...
-
Avid Bioservices Announces Pricing of Public Offering of Common Stock
2/15/2018
Avid Bioservices intends to use the cash for the expansion of its contract manufacturing business and general corporate purposes.
-
Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab
2/12/2018
In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies.
-
Dr. Lias succeeds Steven W. King, who resigned as president and chief executive officer of Peregrine to pursue other professional interests.
-
Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations
11/29/2017
Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry,
-
Avid Bioservices, Inc. Expands Manufacturing Capabilities With Installation And Validation Of Two MilliporeSigma Mobius 2,000-Liter Single-Use Bioreactors In Its Myford Facility
9/25/2017
-
Peregrine Announces Appointment Of Roger J. Lias, Ph.D. As President Of Avid Bioservices, Inc.
9/11/2017